Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
PurposeCollecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poorprognosis, accountings for less than 1% of all renal cancers. To date, no standardtherapy for CDC has been established. The aim of this study is an investigation ofclinicopathologic findings of CDC and correlation of the disease status with a prognosis. Materials and MethodsFrom 1996 to 2009, 35 patients with CDC were treated at eight medical centers. Thediagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy ineight cases. ResultsMedian PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6months (95% CI 0 to 23.3), which showed a statistically significant difference(p=0.01). In addition, among patients with Stage IV, the OS of patients who receiveda palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4months, which was higher than the OS of patients without treatment of 4.5 months. ConclusionCDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments,PFS and OS were short, however, there were some long-term survivors, therefore,conduct of additional research on the predictive markers of the several clinical,pathological differences and their treatments will be necessary.
Abstract
PurposeCollecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poorprognosis, accountings for less than 1% of all renal cancers. To date, no standardtherapy for CDC has been established. The aim of this study is an investigation ofclinicopathologic findings of CDC and correlation of the disease status with a prognosis. Materials and MethodsFrom 1996 to 2009, 35 patients with CDC were treated at eight medical centers. Thediagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy ineight cases. ResultsMedian PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6months (95% CI 0 to 23.3), which showed a statistically significant difference(p=0.01). In addition, among patients with Stage IV, the OS of patients who receiveda palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4months, which was higher than the OS of patients without treatment of 4.5 months. ConclusionCDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments,PFS and OS were short, however, there were some long-term survivors, therefore,conduct of additional research on the predictive markers of the several clinical,pathological differences and their treatments will be necessary.
참고문헌 (19)
- Cohen HT, "Renal-cell carcinoma", N Engl J Med, 353, pp.2477~2490 (2005)
- Verdorfer I, "Characterisation of a collecting duct carcinoma by cytogenetic analysis and comparative genomic hybridisation", Int J Oncol, 13, pp.461~464 (1998)
- Auguet T, "Synchronus renal cell carcinoma and Bellini duct carcinoma : a case report on a rare coincidence", World J Urol, 18, pp.449~451 (2000)
- Srigley JR, "Collecting duct carcinoma of kidney", Semin Diagn Pathol, 15, pp.54~67 (1998)
- Miyamoto H, "Bellini duct carcinoma of the kidney", Urol Int, 48, pp.460~462 (1992)
- Kobayashi N, "Collecting duct carcinoma of the kidney : an immunohistochemical evaluation of the use of antibodies for differential diagnosis", Hum Pathol, 39, pp.1350~1359 (2008)
- Orsola A, "Renal collecting(Bellini)duct carcinoma displays similar characteristics to upper tract urothelial cell carcinoma", Urology, 65, pp.49~54 (2005)
- Dimopoulos MA, "Collecting duct carcinoma of the kidney", Br J Urol, 71, pp.388~391 (1993)
- Oudard S, "Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma : results of a GETUG(Groupe d'Etudes des Tumeurs Uro-Genitales) study", J Urol, 177, pp.1698~1702 (2007)
- Therasse P, "European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
- Mancilla-Jimenez R, "Papillary renal cell carcinoma : a clinical, radiologic, and pathologic study of 34 cases", Cancer, 38, pp.2469~2480 (1976)
- Kim JH, "A case of collecting duct carcinoma of the kidney", Korean J Urol, 33, pp.888~891 (1992)
- Woo JW, "A case of collecting duct carcinoma of kidney", Korean J Urol, 38, pp.551~554 (1997)
- 이지은, "폐와 간전이를 동반한 집합관 신세포암(Bellini관 암) 1예", 대한내과학회지, 77(6), pp.780~786 (2009), 대한내과학회
- Tokuda N, "Collecting duct(Bellini duct)renal cell carcinoma : a nationwide survey in Japan", J Urol, 176, pp.40~43 (2006)
- Chao D, "Collecting duct renal cell carcinoma : clinical study of a rare tumor", J Urol, 167, pp.71~74 (2002)
- Peyromaure M, "Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases", J Urol, 170(4 Pt 1), pp.1138~1140 (2003)
- Mejean A, "Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma?", J Urol, 169, pp.1287~1290 (2003)
- Procopio G, "Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases", Clin Exp Nephrol, 16, pp.464~467 (2012)